21,532 results
Search Results
2. The use of biomarkers to stratify surgical care in women with ovarian cancer: Scientific Impact Paper No. 69 May 2022.
- Author
-
Phelps, D. L., Borley, J. V., Brown, R., Takáts, Z., and Ghaem‐Maghami, S.
- Subjects
- *
OVARIAN cancer , *CANCER patients , *CA 125 test , *BIOMARKERS , *BIOMOLECULES , *CANCER prognosis , *CANCER treatment - Abstract
Plain language summary: Biomarkers may offer unforeseen insights into clinical diagnosis, as well as the likely course and outcome of a condition. In this paper, the focus is on the use of biological molecules found in body fluids or tissues for diagnosis and prediction of outcome in ovarian cancer patients. In cancer care, biomarkers are being used to develop personalised treatment plans for patients based on the unique characteristics of their tumour. This tailoring of care can be used to pursue specific targets identified by biomarkers, or treat the patient according to specific tumour characteristics. Surgery is one of the core treatments for ovarian cancer, whether it is offered in primary surgery or following chemotherapy in delayed surgery. Biomarkers already exist to guide the treatment of tumours with chemotherapy, but very little research has determined the value of biomarkers in tailoring surgical care for ovarian cancer. Such research is required to identify new biomarkers and assess their effectiveness in a clinical setting as well as to help identify specific tumour types to guide surgery. Biomarkers could help to determine the success of removing the disease surgically, or help to identify tumour deposits that persist after chemotherapy. All of these aspects would improve current practice. This Scientific Impact Paper highlights research that may pave the way towards bespoke surgery according to the biological characteristics of a tumour and aid gynaecological oncologists to provide surgical treatment according to individual need, rather than a blanket approach for all. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
3. Conversion from paper to electronic acute care chemotherapy orders.
- Author
-
Offei-nkansah, Gerald and Amerine, Lindsey B
- Subjects
- *
ACADEMIC medical centers , *OUTPATIENT medical care , *CANCER chemotherapy , *CANCER treatment , *CRITICAL care medicine , *HOSPITAL pharmacies , *PHARMACY databases , *INTERPROFESSIONAL relations , *SPECIALTY hospitals , *MEDICATION therapy management , *ELECTRONIC health records - Abstract
Purpose UNC Medical Center converted to an electronic health record (EHR) in 2014. This conversion allowed for the transition of paper chemotherapy orders to be managed electronically. This article describes the process for converting inpatient paper chemotherapy orders into the new EHR in a safe and effective manner. Summary A collaborative interdisciplinary approach to the EHR transition enabled our organization to move from using paper chemotherapy orders to fully electronic chemotherapy treatment plans in both ambulatory and acute care areas. Active chemotherapy orders for acute care inpatients were reviewed and transcribed by two oncology pharmacists in the cancer hospital prior to being signed by an attending physician. The newly input orders were independently verified by two pharmacists in the cancer hospital inpatient pharmacy. Nurse review of the signed and verified treatment plans, along with reconciliation of the medication administration record ensured a safe transition to the new EHR workflow. Providers benefit from the ability to review treatment plans remotely, track changes, and include supportive medications in one consolidated location. The coordinated team effort allowed for a smooth transition with minimal interruptions to patient care. Conclusion The pharmacist-led, multidisciplinary conversion to electronic chemotherapy orders was safe, accurate, and occurred ahead of schedule for the EHR go-live. Advance communication and planning around scheduled inpatient admissions helped to minimize the impact of the transition from paper to electronic treatment plans. Both pharmacist and physician engagement were necessary to ensure a smooth transition for active inpatient treatment plans. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
4. Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societa' Italiana di Nefrologia (SIN) multidisciplinary consensus position paper.
- Author
-
Silvestris, Nicola, Argentiero, Antonella, Cosmai, Laura, Porta, Camillo, Gesualdo, Loreto, Brunori, Giuliano, Brunetti, Oronzo, Rampino, Teresa, Secondino, Simona, Rizzo, Gianpiero, and Pedrazzoli, Paolo
- Subjects
- *
CHRONICALLY ill , *CANCER patients , *KIDNEY diseases , *CHRONIC kidney failure , *CANCER treatment , *BIOAVAILABILITY - Abstract
• Most of target agents can be used with the same patterns and the same dosage in mild and moderate renal impairment. • It is difficult to draw scientific supported conclusions in cancer patients with severe, end-stage renal disease or HD. • Although renal toxicity of biological agents can be overcome by HD treatment, caution in these settings is still warranted. • A strong cooperation among oncologists, nephrologists and pharmacists is unavoidable to provide an optimal management for these patients. The increasing availability of novel biological anticancer agents has greatly improved the outcome of several cancer patients; unfortunately, data regarding efficacy, safety and pharmacokinetics of many of these agents in patients with chronic renal disease or on hemodialysis are scanty. Furthermore these results are controversial and a treatment strategy has not yet been established. Therefore, the Associazione Italiana di Oncologia Medica and the Società italiana di Nefrologia undertook the present work aiming at providing health professionals with a tool for easier clinical management of target therapies in this setting of patients. A web-based search of MEDLINE/PubMed library data published from 2000 to June 2018 has been performed. More than one hundred papers, including recommendations and expert opinions, were selected and discussed by the authors. A panel of experts provided additional biological and clinical information, helping in clarifying some issues in the absence of clear-cut information from the literature. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
5. Peptide modified paper based impedimetric immunoassay with nanocomposite electrodes as a point-of-care testing of Alpha-fetoprotein in human serum.
- Author
-
Moazeni, Maryam, Karimzadeh, Fathallah, and Kermanpur, Ahmad
- Subjects
- *
POINT-of-care testing , *ALPHA fetoproteins , *BLOOD serum analysis , *CANCER treatment , *MICROFLUIDIC devices - Abstract
Treatment for cancer depends on the type of cancer, and the stage or its development, and thus the need for point-of-care technology that can allow rapid and precise detection of biomarkers is increasing. Here, we present a simple on chip electrical detection of Alpha-fetoprotein (AFP). We rely on using a novel peptide modified plastic-paper microfluidic chips to perform efficient and specific impedimetric detection of AFP in human serum. The chips are prepared from a lower sheet of plastic and upper layer of cellulose chromatography paper modified with silver-20 wt% graphene printed electrodes. Diphenylalanine (FF) was proposed to involve in detection zone of the fabricated microchips in order to improve the sensing performance and the stability of immobilized antibodies according to amine-aldehyde reaction. The target protein is captured on the surface of microchips using specific monoclonal antibodies and the electrical response of the chip is monitored in the presence and absence of different concentrations of AFP. The influence of several parameters including the material types for screen printing of electrodes, FF concentrations, solvent and pH of FF solution on electrical response and cellulose fibers morphology was explored. The impedance measurements of AFP on the fabricated microchip in the optimized parameters exhibited a detection limit of 1 and 10 ng ml −1 in PBS and plasma, respectively. This platform developed here can be adopted to develop systems for rapid detection of biomarkers using portable electric devices. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
6. Photobiomodulation therapy in management of cancer therapy-induced side effects: WALT position paper 2022.
- Author
-
Robijns, Jolien, Nair, Raj G., Lodewijckx, Joy, Arany, Praveen, Barasch, Andrei, Bjordal, Jan M., Bossi, Paolo, Chilles, Anne, Corby, Patricia M., Epstein, Joel B., Elad, Sharon, Fekrazad, Reza, Fregnani, Eduardo Rodrigues, Genot, Marie-Thérèse, Ibarra, Ana M. C., Hamblin, Michael R., Heiskanen, Vladimir, Hu, Ken, Klastersky, Jean, and Lalla, Rajesh
- Subjects
PHOTOBIOMODULATION therapy ,TRISMUS ,HEMATOPOIETIC stem cell transplantation ,CANCER treatment ,VOICE disorders ,HAND-foot syndrome ,ORAL medicine - Abstract
Disclaimer: This article is based on recommendations from the 12th WALT Congress, Nice, October 3-6, 2018, and a follow-up review of the existing data and the clinical observations of an international multidisciplinary panel of clinicians and researchers with expertise in the area of supportive care in cancer and/or PBM clinical application and dosimetry. This article is informational in nature. As with all clinical materials, this paper should be used with a clear understanding that continued research and practice could result in new insights and recommendations. The review reflects the collective opinion and, as such, does not necessarily represent the opinion of any individual author. In no event shall the authors be liable for any decision made or action taken in reliance on the proposed protocols. Objective: This position paper reviews the potential prophylactic and therapeutic effects of photobiomodulation (PBM) on side effects of cancer therapy, including chemotherapy (CT), radiation therapy (RT), and hematopoietic stem cell transplantation (HSCT). Background: There is a considerable body of evidence supporting the efficacy of PBM for preventing oral mucositis (OM) in patients undergoing RT for head and neck cancer (HNC), CT, or HSCT. This could enhance patients’ quality of life, adherence to the prescribed cancer therapy, and treatment outcomes while reducing the cost of cancer care. Methods: A literature review on PBM effectiveness and dosimetry considerations for managing certain complications of cancer therapy were conducted. A systematic review was conducted when numerous randomized controlled trials were available. Results were presented and discussed at an international consensus meeting at the World Association of photobiomoduLation Therapy (WALT) meeting in 2018 that included world expert oncologists, radiation oncologists, oral oncologists, and oral medicine professionals, physicists, engineers, and oncology researchers. The potential mechanism of action of PBM and evidence of PBM efficacy through reported outcomes for individual indications were assessed. Results: There is a large body of evidence demonstrating the efficacy of PBM for preventing OM in certain cancer patient populations, as recently outlined by the Multinational Association for Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Building on these, the WALT group outlines evidence and prescribed PBM treatment parameters for prophylactic and therapeutic use in supportive care for radiodermatitis, dysphagia, xerostomia, dysgeusia, trismus, mucosal and bone necrosis, lymphedema, hand-foot syndrome, alopecia, oral and dermatologic chronic graft-versushost disease, voice/speech alterations, peripheral neuropathy, and late fibrosis amongst cancer survivors. Conclusions: There is robust evidence for using PBM to prevent and treat a broad range of complications in cancer care. Specific clinical practice guidelines or evidence-based expert consensus recommendations are provided. These recommendations are aimed at improving the clinical utilization of PBM therapy in supportive cancer care and promoting research in this field. It is anticipated these guidelines will be revised periodically. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Ultrasensitive electrochemiluminescence assay of tumor cells and evaluation of H2O2 on a paper-based closed-bipolar electrode by in-situ hybridization chain reaction amplification.
- Author
-
Ge, Shenguang, Zhao, Jinge, Wang, Shaopeng, Lan, Feifei, Yan, Mei, and Yu, Jinghua
- Subjects
- *
ELECTROCHEMILUMINESCENCE , *CANCER cells , *HYDROGEN peroxide , *CEROGRAPHY , *GOLD nanoparticles , *BIOELECTRONICS , *CANCER treatment - Abstract
In this manuscript, a disposable paper-based analytical device comprised of a closed bipolar electrode (BPE) was fabricated for the ultrasensitive electrochemiluminescence (ECL) detection of intracellular H 2 O 2 and the number of cancer cells. In this approach, wax printing was used to fabricated reaction zone, and carbon ink-based BPE and driving electrodes were screen-printed into the paper. AuPd nanoparticles (NPs), which served as a carrier of the capture aptamer and as the catalyst for the ECL reaction of luminol and H 2 O 2 , were used to modify the BPE. Luminol/Au NPs were attached to the surface of the captured cells via hybridation chain reaction with two hairpin structure DNA labelled luminol/Au NPs. In the stimulation of phorbol myristate acetate, The coreactant H 2 O 2 was released from the target cells. The ECL response of the luminol-H 2 O 2 system was related to the number of cancer cells in the testing buffer, which served as a quantitative signal for the determination of cancer cells and the concentration of H 2 O 2 . In order to decrease the external voltage, K 3 [Fe(CN) 6 ] was introduced in the cathode resevoir of BPE because it gained electrons at the cathode more easily than oxygen. The ECL intensity was quantitatively related to the concentration of MCF-7 in the range of 1.0 × 10 2 –1.0 × 10 7 cells/mL. The detection limit was 40 cells/mL and it showed good specificity for cells with high overexpression of mucin-1 receptor, it was concluded that the developed protocol could be effectively utilized for the detection of MCF-7 cells. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
8. European Society for Medical Oncology (ESMO) position paper on supportive and palliative care.
- Author
-
Jordan, K, Aapro, M, Kaasa, S, Ripamonti, C I, Scotté, F, Strasser, F, Young, A, Bruera, E, Herrstedt, J, and Keefe, D
- Subjects
- *
PALLIATIVE treatment , *ANTINEOPLASTIC agents , *CANCER treatment , *INDIVIDUALIZED medicine , *QUALITY of life - Abstract
Oncology has come a long way in addressing patients' quality of life, together with developing surgical, radio-oncological and medical anticancer therapies. However, the multiple and varying needs of patients are still not beingmet adequately as part of routine cancer care. Supportive and palliative care interventions should be integrated, dynamic, personalised and based on best evidence. They should start at the time of diagnosis and continue through to end-of-life or survivorship. ESMO is committed to excellence in all aspects of oncological care during the continuum of the cancer experience. Following the 2003 ESMO stand on supportive and palliative care (Cherny N, Catane R, Kosmidis P. ESMO takes a stand on supportive and palliative care. Ann Oncol 2003; 14(9): 1335-1337), this position paper highlights the evolving and growing gap between the needs of cancer patients and the actual provision of care. The concept of patient-centred cancer care is presented along with key requisites and areas for further work. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
9. Overcoming barriers to timely recognition and treatment of cancer cachexia: Sharing Progress in Cancer Care Task Force Position Paper and Call to Action.
- Author
-
Arends, Jann, Muscaritoli, Maurizio, Anker, Stefan, Audisio, Riccardo, Barazzoni, Rocco, Bosnjak, Snezana, Bossi, Paolo, Bowman, Jacqueline, Gijssels, Stefan, Krznarić, Željko, Strasser, Florian, and Aapro, Matti
- Subjects
- *
CACHEXIA , *TASK forces , *CANCER treatment , *MUSCLE mass , *SKELETAL muscle - Abstract
Cachexia is a life-threatening disorder affecting an estimated 50–80% of cancer patients. The loss of skeletal muscle mass in patients with cachexia is associated with an increased risk of anticancer treatment toxicity, surgical complications and reduced response. Despite international guidelines, the identification and management of cancer cachexia remains a significant unmet need owing in part to the lack of routine screening for malnutrition and suboptimal integration of nutrition and metabolic care into clinical oncology practice. In June 2020, Sharing Progress in Cancer Care (SPCC) convened a multidisciplinary task force of medical experts and patient advocates to examine the barriers preventing the timely recognition of cancer cachexia, and provide practical recommendations to improve clinical care. This position paper summarises the key points and highlights available resources to support the integration of structured nutrition care pathways. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. NANOROBOTS AND ITS ADVANCEMENTS IN MEDICAL FIELD.
- Author
-
S., ATHEENA MILAGI PANDIAN, MURUGAN, RASHIKA, N., SRI MANOJ KUMAR, and M., SUDHERSON
- Subjects
NANOTECHNOLOGY ,ROBOTICS ,ONCOLOGY ,DRUG delivery systems ,CANCER treatment - Abstract
This paper reviews the potential applications of nanorobots in oncology, cardiology, neurology, respiratory medicine, and nephrology, emphasizing their role in precision drug delivery, cancer therapy, diagnostic procedures, surgical interventions, and disease management. Nanorobots perform particular tasks with great accuracy and precision. They are capable of sensing the environment, transmitting signals to technicians, processing information, and exhibiting intelligence at the nanoscale. They are utilized for treating various illnesses in medical specialties such as cardiology, respiratory, neurology, nephrology, and ophthalmology. Nanorobots can be primarily used in surgery. The material characteristics, such as non-toxicity and biocompatibility, are critical for their safe interaction within the human body. Furthermore, various insertion methods, including intravenous and intra-tumoral injections, are explored. Future advancements are anticipated to enhance multifunctionality, targeting specificity, and integration with artificial intelligence, leading to more autonomous and efficient nanorobots. The integration of nanorobots in medical practice could revolutionize healthcare by offering minimally invasive, highly precise, and personalized treatment options, significantly improving patient outcomes and quality of life. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Evidence-Based Dietetic Practice: EFAD Discussion Paper on Challenges for Implementation, Education, Research, and Lifelong Learning.
- Subjects
CONTINUING education ,CANCER patient care ,PHYSICAL activity ,HEALTH outcome assessment ,CANCER treatment - Published
- 2023
- Full Text
- View/download PDF
12. Recommended Resources for Cancer Patients: Transitioning from Paper Pathfinders to LibGuides.
- Author
-
Prilop, Valerie, Justice, Adela V., and Brackeen, Elizabeth
- Subjects
- *
CANCER patients , *CANCER treatment , *HOSPITAL libraries , *MARKETING , *WEB development , *PATIENT education , *SPECIALTY hospitals - Abstract
In 2015, The Learning Center, a consumer health library at MD Anderson Cancer Center, embarked on a project to translate paper pathfinders into online Recommended Resources in Springshare’s LibGuides platform. This project was successfully undertaken by a small staff of librarians and health education specialists with a range of technical skills and allowed online access to resources available both online and in The Learning Center. This article briefly addresses the activities and decisions leading up to the adoption of LibGuides, outlines the process of creating more than 40 online Recommended Resources, and describes the outcomes to date. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
13. DIAGNOSIS, TREATMENT, AND PREVENTION OF CARDIOVASCULAR TOXICITY RELATED TO ANTI-CANCER TREATMENT IN CLINICAL PRACTICE: AN OPINION PAPER FROM THE WORKING GROUP ON CARDIO-ONCOLOGY OF THE KOREAN SOCIETY OF ECHOCARDIOGRAPHY.
- Author
-
HYUNGSEOP KIM, WOO-BAEK CHUNG, KYOUNG IM CHO, BONG-JOON KIM, JEONG-SOOK SEO, SEONG-MI PARK, HAK JIN KIM, JU-HEE LEE, EUN KYOUNG KIM, and HO-JOONG YOUN
- Subjects
- *
CARDIOTOXICITY , *ANTINEOPLASTIC agents , *CANCER treatment - Abstract
Cardiovascular (CV) toxicity associated with anti-cancer treatment is commonly encountered and raises critical problems that often result in serious morbidity or mortality. Most cardiac toxicides are related to the cumulative dose of chemotherapy; however, the type of chemotherapy, concomitant agents, and/or conventional CV risk factors have been frequently implicated in CV toxicity. Approximately half of the patients exhibiting CV toxicity receive an anthracycline-based regimen. Therefore, serologic biomarkers or cardiac imagings are important during anti-cancer treatment for early detection and the decision of appropriate management of cardiotoxicity. However, given the difficulty in determining a causal relationship, a multidisciplinary collaborative approach between cardiologists and oncologists is required. In this review, we summarize the CV toxicity and focus on the role of cardiac imaging in management strategies for cardiotoxicity associated with anti-cancer treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
14. Incorporating Digital Tools to Improve Clinical Trial Infrastructure: A White Paper From the Digital Engagement Committee of SWOG.
- Author
-
Dizon, Don S., Sedrak, Mina, Lewis, Mark A., Cook, Elise, Fisch, Michael J., Klemp, Jennifer R., Sommers, Jonathan, Ciccarella, AnneMarie, Gralow, Julie, Lawton, Wendy, and Nichols, Craig
- Subjects
- *
MEDICAL technology , *CANCER treatment , *CLINICAL trials , *CANCER patients , *INTERNET in medicine - Abstract
Progress toward improvement in cancer therapy relies on clinical trials. Yet, only a minority of eligible patients with cancer enroll as a result of multiple barriers at the patient, investigator, center, and national level. However, the rise of the Internet and mobile technology has created a slew of tools with medical applications, from Web sites to apps to social media platforms, all of which may aide clinicians in our quest to improve the clinical research enterprise. SWOG is one of five members in the National Cancer Institute's National Clinical Trials Network--the nation's oldest and largest publicly funded cancer research network--and is taking a leadership role in exploring and testing the promise of digital engagement through the empaneling of the Digital Engagement Committee. This article outlines the mission, principles, and priorities of the Digital Engagement Committee and proposes how this work may inform the use of digital tools for the cancer research community and, hopefully, translate to improved outcomes for our patients. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
15. Paper-based electrochemiluminescence origami cyto-device for multiple cancer cells detection using porous AuPd alloy as catalytically promoted nanolabels.
- Author
-
Wu, Ludan, Ma, Chao, Ge, Lei, Kong, Qingkun, Yan, Mei, Ge, Shenguang, and Yu, Jinghua
- Subjects
- *
ELECTROCHEMILUMINESCENCE , *CANCER cells , *CANCER treatment , *POROUS materials , *BIOSENSORS , *GOLD alloys , *MICROFLUIDIC devices , *GOLD electrodes - Abstract
The detection of cancer cells is important and fundamental for cancer diagnosis and therapy, which has attracted considerable interest recently. Although traditional cyto-sensors have been widely explored due to their high sensitivity and selectivity, it is still a challenge to develop a low-cost, portable, disposable, fast, and easy-to-use cancer cell detection method for applying in the field of cancer diagnosis and therapy. Herein, to address these challenges, we developed a microfluidic paper-based electrochemiluminescence origami cyto-device (μ-PECLOC), in which aptamers modified 3D macroporous Au-paper electrodes were employed as the working electrodes and efficient platforms for the specific cancer cells capture. Owing to the effective disproportionation of hydrogen peroxide and specific recognition of mannose on cell surface, concanavalin-A conjugated porous AuPd alloy nanoparticles were introduced into this μ-PECLOC as the catalytically promoted nanolabels for peroxydisulfate ECL system. Under the optimal conditions, the proposed μ-PECLOC exhibited excellent analytical performance with good stability, reproducibility, and accuracy, towards the cyto-sensing of four types of cancer cells indicating the potential applications to facilitate effective and multiple early cancer diagnosis and clinical treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
16. Upgrading the Chemotherapy Consent: Trading in Paper for Tablet.
- Author
-
Wu, Lesley, Smith, Cardinale B., Parra, Jessica, Liu, Mark, Theroux, Haley Hines, and Bhardwaj, Aarti S.
- Subjects
AUDITING ,SPECIALTY hospitals ,PROBLEM solving ,CANCER chemotherapy ,INFORMED consent (Medical law) ,CANCER patients ,CANCER treatment ,HUMAN services programs ,HEALTH care teams ,DESCRIPTIVE statistics ,PATIENT compliance ,MEDICAL needs assessment ,BREAST tumors - Abstract
PURPOSE Our institution participated in the Oncology Care Model, which required us to include many of the 13 elements of the National Academy of Medicine (NAM) care plan into care pathways for our patients. We optimized our existing chemotherapy consent process to meet this need and maximized completion. METHODS Our multidisciplinary committee developed a three-phase Plan-Do-Study-Act process in our breast cancer clinic: (1) update and educate providers on our paper chemotherapy form with multiple components of the NAM care plan including prognosis and treatment effects on quality of life; (2) piloted an electronic chemotherapy consent form to decrease the administrative burden; and (3) autopopulated fields within the electronic consent. We assessed feedback after cycle 1 and created a Pareto chart. The outcome measure was percent completion of chemotherapy consent documents. RESULTS Baseline monthly random chart audit of 40 patients revealed 20% of paper chemotherapy consent forms were completed in their entirety among patients. When we re-educated clinicians about the new paper consent containing the NAM elements, compliance rose to nearly 30%. A Pareto chart confirmed that content redundancy and wordiness were leading to under-completion. After creating and piloting the electronic consent, compliance increased to 90%. Finally, autopopulation with drop-down selections increased and sustained completion to 100%. CONCLUSION Incorporating regulatory requirements into an existing workflow using Plan-Do-Study-Act methodology can reduce administrative burden on clinicians. Additional use of innovative technology can further increase clinician compliance with regulatory requirements while delivering high-value quality care to patients with cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
17. Examining Guidelines and New Evidence in Oncology Nutrition: a Position Paper on Gaps and Opportunities in Multimodal Approaches to Improve Patient Care.
- Author
-
Prado, Carla M., Laviano, Alessandro, Gillis, Chelsia, Sung, Anthony D., Gardner, Maureen, Yalcin, Suayib, Dixon, Suzanne, Newman, Shila M., Bastasch, Michael D., Sauer, Abby C., Hegazi, Refaat, and Chasen, Martin R.
- Subjects
NUTRITION ,PATIENT care ,MUSCLE mass ,HEALTH outcome assessment ,CANCER treatment - Abstract
Malnutrition, muscle loss, and cachexia are prevalent in cancer and remain key challenges in oncology today. These conditions are frequently underrecognized and undertreated and have devastating consequences for patients. Early nutrition screening/assessment and intervention are associated with improved patient outcomes. As a multifaceted disease, cancer requires multimodal care that integrates supportive interventions, specifically nutrition and exercise, to improve nutrient intake, muscle mass, physical functioning, quality of life, and treatment outcomes. An integrated team of healthcare providers that incorporates societies' recommendations into clinical practice can help achieve the best possible outcomes. A multidisciplinary panel of experts in oncology, nutrition, exercise, and medicine participated in a 2-day virtual roundtable in October 2020 to discuss gaps and opportunities in oncology nutrition, alone and in combination with exercise, relative to current evidence and international societies' recommendations. The panel recommended five principles to optimize clinical oncology practice: (1) position oncology nutrition at the center of multidisciplinary care; (2) partner with colleagues and administrators to integrate a nutrition care process into the multidisciplinary cancer care approach; (3) screen all patients for malnutrition risk at diagnosis and regularly throughout treatment; (4) combine exercise and nutrition interventions before (e.g., prehabilitation), during, and after treatment as oncology standard of care to optimize nutrition status and muscle mass; and (5) incorporate a patient-centered approach into multidisciplinary care. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
18. Title of presented paper: Chemobrain after anticancer treatment - when the necessary treatment has unpleasant consequences.
- Author
-
Monika, Błądek, Karolina, Drygała, and Gabriela, Barszcz
- Subjects
ANTINEOPLASTIC agents ,CANCER treatment ,COGNITION ,COGNITION disorders ,IMMUNOTHERAPY - Abstract
Introduction and aim. Over the last few decades, there has been tremendous progress in the treatment of cancer. Unfortunately, anti-cancer therapies, although necessary and increasingly effective, still carry many side effects. One of these effects is the chemobrain -- cognitive disorders resulting from strong chemotherapy. The aim of this paper is to review available knowledge of chemobrain. Material and methods. The paper reviews articles available in the PubMed medical database, searched with the phrases "chemobrain", "chemobrain cancer" from the years 2015-2023 which are reviews, systematic reviews or meta-analyses. 41 results were obtained, of which 13 articles were used for the final analysis after the selection of papers strictly related to the issue of chemobrain. Analysis of literature. The occurrence of chemobrain is associated with impaired cognitive abilities, problems with concentration, and memory loss. It may occur only during treatment or persist even after its completion. According to the data, chemobrain occurs much more often as a complication of traditional chemotherapy than in the case of immunotherapy. The mechanism of chemobrain formation is not known. A combination of oxygen radical production and cytokine dysregulation is suspected as an inducer of this complication. Chemobrain treatment strategies remain under development. At the moment, non-pharmacological methods are used in the treatment, such as regular physical exercise, mental exercise, or a diet including omega-3 fatty acids. Pharmacological treatment is still under development and research. Conclusion. Chemobrain is a medical complication that can have a serious psychological impact on patients undergoing anti-cancer therapy, so further research is needed to better understand the mechanism of this phenomenon, which will allow the development of new treatments and possible ways to prevent the occurrence of chemobrain. [ABSTRACT FROM AUTHOR]
- Published
- 2023
19. A multicenter paper-based and web-based system for collecting patient-reported outcome measures in patients undergoing local treatment for prostate cancer: first experiences.
- Author
-
Kowalski, Christoph, Roth, Rebecca, Carl, Günther, Feick, Günter, Oesterle, Alisa, Hinkel, Andreas, Steiner, Thomas, Brock, Marko, Kaftan, Björn, Borowitz, Rainer, Zantl, Niko, Heidenreich, Axel, Neisius, Andreas, Darr, Christopher, Bolenz, Christian, Beyer, Burkhard, Pfitzenmaier, Jesco, Brehmer, Bernhard, Fichtner, Jan, and Haben, Björn
- Subjects
PROSTATE cancer ,CANCER patients ,ACQUISITION of data ,IMPLEMENTATION (Social action programs) ,MEDICAL care ,PROSTATE tumors treatment ,RESEARCH ,SPECIALTY hospitals ,RADICAL prostatectomy ,HEALTH outcome assessment ,CANCER treatment ,CONTENT mining ,MEDICAL care research ,QUESTIONNAIRES ,DESCRIPTIVE statistics ,CHI-squared test ,AUTOMATIC data collection systems ,RESEARCH funding ,DATA analysis software ,DECISION making in clinical medicine ,LONGITUDINAL method ,PROSTATE tumors ,DISEASE risk factors ,EVALUATION - Abstract
Purpose: To give an overview of the multicenter Prostate Cancer Outcomes (PCO) study, involving paper-based and web-based collection of patient-reported outcome measures (PROM) in patients undergoing local treatment for prostate cancer in certified centers in Germany. The PCO study is part of the larger Movember-funded TrueNTH Global Registry. The article reports on the study's design and provides a brief progress report after the first 2 years of data collection. Methods: Prostate cancer centers (PCCs) certified according to German Cancer Society requirements were invited to participate in collecting patient-reported information on symptoms and function before and at least once (at 12 months) after treatment. The data were matched with disease and treatment information. This report describes progress in patient inclusion, response rate, and variations between centers relative to online/paper use, and also data quality, including recruitment variations relative to treatment in the first participating PCCs. Results: PCC participation increased over time; 44 centers had transferred data for 3094 patients at the time of this report. Patient recruitment varied widely across centers. Recruitment was highest among patients undergoing radical prostatectomy. The completeness of the data was good, except for comorbidity information. Conclusions: The PCO study benefits from a quality improvement system first established over 10 years ago, requiring collection and harmonization of a predefined clinical dataset across centers. Nevertheless, establishing a PROM routine requires substantial effort on the part of providers and constant monitoring in order to achieve high-quality data. The findings reported here may be useful for guiding implementation in similar initiatives. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
20. Rapid detection of urokinase plasminogen activator using flexible paper-based graphene-gold platform.
- Author
-
Sharma, Bipin, Parajuli, Prakash, and Podila, Ramakrishna
- Subjects
PLASMINOGEN activators ,METASTASIS ,CANCER diagnosis ,CANCER treatment ,FLUORESCENCE - Abstract
Many studies have shown that urokinase plasminogen activator (uPA) is causally involved in promoting cancer invasion and metastasis. Thus, monitoring uPA levels could be very useful in cancer diagnosis, identification of initial metastasis, and guiding cancer treatment. Here, the authors developed a novel and scalable uPA sensor based on a graphene-gold nanoparticle platform that uses fluorescence of quantum dots to rapidly (<1 h) detect uPA up to 100 pM. Indeed, the authors' sensor is highly selective and showed an ability to sense up to 100 pM uPA even in the presence of complex biological milieu such as the fetal bovine serum. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
21. Extraction Paper Chromatography Technique for the Radionuclidic Purity Evaluation of 90Y for Clinical Use.
- Author
-
Pandey, Usha, Dhami, Prem S., Jagesia, Poonam, Venkatesh, Meera, and Pillai, M. R. A.
- Subjects
- *
CHROMATOGRAPHIC analysis , *LIQUID scintillation counting , *CANCER treatment , *THERAPEUTICS , *PAPER chromatography , *BONES , *STRONTIUM , *MEDICAL care , *CHELATES - Abstract
Yttrium-90 used for therapy should be of very high radionuclidic (RN) purity (>99.998%) as the most probable contaminant, strontium-90, is a bone seeker with a maximum permissible body burden of 74 kBq (2 μCi) only. None of the current known methods of RN purity estimations is adequate to reliably measure the 90Sr RN impurity at such low levels. Our aim was to develop a reliable technique to accurately determine the amount of 90Sr in 90Y used for therapy. This new technique combines chelate-based extraction with paper chromatography using paper impregnated with 2-ethylhexyl, 2-ethylhexylphosphonic acid (KSM-17), which is a 90Y-specific chelator. A PC strip impregnated with KSM-17 at the point of spotting is used for chromatography. Upon development with normal saline, 90Sr moves to the solvent front leaving 90Y completely chelated and retained at the point of spotting. The activity at the solvent front (90Sr) is quantified by liquid scintillation counting, and the data are compared with the total applied activity to provide the RN purity of the test solution. The method has a sensitivity of ⩾74 kBq (2 μCi) of 90Sr per 37 GBq (1 Ci) of 90Y. This novel, innovative, and simple technique offers a reliable solution to the unanswered problem of estimation of 90Sr content in 90Y used for cancer therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
22. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.
- Author
-
Champiat, S., Lambotte, O., Barreau, E., Belkhir, R., Berdelou, A., Carbonnel, F., Cauquil, C., Chanson, P., Collins, M., Durrbach, A., Ederhy, S., Feuillet, S., François, H., Lazarovici, J., Le Pavec, J., De Martin, E., Mateus, C., Michot, J. -M., Samuel, D., and Soria, J. -C.
- Subjects
- *
IMMUNOTOXICOLOGY , *CANCER immunotherapy , *THERAPEUTIC use of monoclonal antibodies , *MELANOMA treatment , *CANCER treatment , *NON-small-cell lung carcinoma , *TARGETED drug delivery - Abstract
Monoclonal antibodies targeted against the immune checkpoint molecules CTLA-4 and PD-1 have recently obtained approval for the treatment of metastatic melanoma and advanced/refractory non small-cell lung cancers. Therefore, their use will not be limited anymore to selected hospitals involved in clinical trials. Indeed, they will be routinely prescribed in many cancer centers across the world. Besides their efficacy profile, these immune targeted agents also generate immune-related adverse events (irAEs). This new family of dysimmune toxicities remains largely unknown to the broad oncology community. Although severe irAEs remain rare (~10% of cases under monotherapy), they can become life-threatening if not anticipated and managed appropriately. Over the last 5 years, Gustave Roussy has accumulated a significant experience in the prescription of immune checkpoint blockade (ICB) antibodies and the management of their toxicities. Together with the collaboration of Gustave Roussy's network of organ specialists with expertise in irAEs, we propose here some practical guidelines for the oncologist to help in the clinical care of patients under ICB immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
23. Use Cases Requiring Privacy-Preserving Record Linkage in Paediatric Oncology.
- Author
-
Hayn, Dieter, Kreiner, Karl, Sandner, Emanuel, Baumgartner, Martin, Jammerbund, Bernhard, Falgenhauer, Markus, Düster, Vanessa, Devi-Marulkar, Priyanka, Schleiermacher, Gudrun, Ladenstein, Ruth, and Schreier, Guenter
- Subjects
CANCER treatment ,TUMORS in children ,DATABASE management ,PRIVACY ,MEDICAL record linkage ,CHILDREN'S hospitals ,MEDICAL ethics ,SPECIALTY hospitals - Abstract
Simple Summary: Large datasets concerning childhood cancers are rare. Therefore, it is important to fully exploit all available data, which are distributed over several resources, including biomaterials, images, clinical trials, and registries. With privacy-preserving record linkage (PPRL), datasets can be merged, without disclosing the patients' identities. Although PPRL is already implemented or described in various settings, use case descriptions are fragmented and incomplete. The present paper gives an overview of current and future use cases of PPRL in childhood cancer. We screened the literature, projects, and trial protocols, analysed a hypothetical patient journey, and discussed use cases with experts. All the identified use cases were structured along six key dimensions. We conclude that PPRL is a key concept in childhood cancer. Therefore, PPRL strategies should already be considered when starting research projects, to avoid distributed data silos, to maximise the knowledge derived from collected data, and, ultimately, to improve outcomes for children with cancer. Large datasets in paediatric oncology are inherently rare. Therefore, it is paramount to fully exploit all available data, which are distributed over several resources, including biomaterials, images, clinical trials, and registries. With privacy-preserving record linkage (PPRL), personalised or pseudonymised datasets can be merged, without disclosing the patients' identities. Although PPRL is implemented in various settings, use case descriptions are currently fragmented and incomplete. The present paper provides a comprehensive overview of current and future use cases for PPRL in paediatric oncology. We analysed the literature, projects, and trial protocols, identified use cases along a hypothetical patient journey, and discussed use cases with paediatric oncology experts. To structure PPRL use cases, we defined six key dimensions: distributed personalised records, pseudonymisation, distributed pseudonymised records, record linkage, linked data, and data analysis. Selected use cases were described (a) per dimension and (b) on a multi-dimensional level. While focusing on paediatric oncology, most aspects are also applicable to other (particularly rare) diseases. We conclude that PPRL is a key concept in paediatric oncology. Therefore, PPRL strategies should already be considered when starting research projects, to avoid distributed data silos, to maximise the knowledge derived from collected data, and, ultimately, to improve outcomes for children with cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. EORTC elderly task force position paper: Approach to the older cancer patient
- Author
-
Pallis, A.G., Fortpied, C., Wedding, U., Van Nes, M.C., Penninckx, B., Ring, A., Lacombe, D., Monfardini, S., Scalliet, P., and Wildiers, H.
- Subjects
- *
GERIATRIC oncology , *DISEASES in older people , *CLINICAL trials , *DISEASE incidence , *CANCER treatment ,AGE factors in cancer - Abstract
As a result of an increasing life expectancy, the incidence of cancer cases diagnosed in the older population is rising. Indeed, cancer incidence is 11-fold higher in persons over the age of 65 than in younger ones. Despite this high incidence of cancer in older patients, solid data regarding the most appropriate approach and best treatment for older cancer patients are still lacking, mostly due to under-representation of these patients in prospective clinical trials. The clinical behaviour of common malignant diseases, e.g. breast, ovarian and lung cancers, lymphomas and acute leukaemias, may be different in older patients because of intrinsic variation of the neoplastic cells and the ability of the tumour host to support neoplastic growth. The decision to treat or not these patients should be based on patients’ functional age rather than the chronological age. Assessment of patients’ functional age includes the evaluation of health, functional status, nutrition, cognition and the psychosocial and economic context. The purpose of this paper is to focus on the influence of age on cancer presentation and cancer management in older cancer patients and to provide suggestions on clinical trial development and methodology in this population. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
25. A structured review and theme analysis of papers published on ‘quality of life’ in head and neck cancer: 2000–2005
- Author
-
Rogers, S.N., Ahad, S.A., and Murphy, A.P.
- Subjects
- *
QUALITY of life , *MEDICAL research , *CANCER patients , *CANCER treatment , *CLINICAL trials - Abstract
Summary: Over the past 10 years, quality of life (QOL) has been increasingly recognised as an important outcome parameter in head and neck cancer. Validated questionnaires have emerged and there has been an increase in the number of papers published each year. The aim of this article is to review the literature over the past five years (2000–2005 inclusive), to identify papers reporting outcomes using patient self-competed questionnaires and group these into themes. The tabulated summary allows for the areas of health related quality of life research to be identified and to explore issues that are perhaps deficit in the literature. The three authors independently searched the literature published in the English language using the ISI search engine with cross-reference using Pub Med and Ovid. The search terms were; quality of life, questionnaire, and head and neck cancer. Studies were placed in to one of five themes. There were 165 studies identified. The numbers in each theme were predictors of QOL [Hassanein KA, Musgrove BT, Bradbury E. Functional status of patients with oral cancer and its relation to style of coping, social support and psychological status. Br J Oral Maxillofac Surg 2001;39:340–5.], functional outcome [Klug C, Neuburg J, Glaser C, Schwarz B, Kermer C, Millesi W. Quality of life 2–10 years after combined treatment for advanced oral and oropharyngeal cancer. Int J Oral Maxillofac Surg 2002;31:664–9.], questionnaire development [Hanna E, Sherman A, Cash D, Adams D, Vural E, Fan CY, et al. Quality of life for patients following total laryngectomy vs chemoradiation for laryngeal preservation. Arch Otolaryngol Head Neck Surg 2004;130:875–9.], randomised clinical trials [Kanatas AN, Rogers SN. A national survey of health-related quality of life questionnaires in head and neck oncology. Ann R Coll Surg Engl 2004;86:6–10.], and reviews [Kanatas AN, Rogers SN. A national survey of health-related quality of life questionnaires in head and neck oncology. Ann R Coll Surg Engl 2004;86:6–10.]. Although many facets of HRQOL following head and neck cancer have been explored over the last five years the paper identifies issues where research is still lacking. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
26. Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
- Author
-
Bennett, Antonia V., Dueck, Amylou C., Mitchell, Sandra A., Mendoza, Tito R., Reeve, Bryce B., Atkinson, Thomas M., Castro, Kathleen M., Denicoff, Andrea, Rogak, Lauren J., Harness, Jay K., Bearden, James D., Bryant, Donna, Siegel, Robert D., Schrag, Deborah, Basch, Ethan, and National Cancer Institute PRO-CTCAE Study Group
- Subjects
CANCER treatment ,DISEASE complications ,DRUG tablets ,INTRAVENOUS therapy ,DRUG administration ,TUMOR treatment ,TUMORS & psychology ,ANTINEOPLASTIC agents ,CROSSOVER trials ,DRUG side effects ,HEALTH outcome assessment ,POCKET computers ,QUESTIONNAIRES ,RADIATION injuries ,RADIOTHERAPY ,RESEARCH evaluation ,RESEARCH funding ,SELF-evaluation ,TERMS & phrases - Abstract
Background: PRO-CTCAE is a library of items that measure cancer treatment-related symptomatic adverse events (NCI Contracts: HHSN261201000043C and HHSN 261201000063C). The objective of this study is to examine the equivalence and acceptability of the three data collection modes (Web-enabled touchscreen tablet computer, Interactive voice response system [IVRS], and paper) available within the US National Cancer Institute (NCI) Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) measurement system.Methods: Participants (n = 112; median age 56.5; 24 % high school or less) receiving treatment for cancer at seven US sites completed 28 PRO-CTCAE items (scoring range 0-4) by three modes (order randomized) at a single study visit. Subjects completed one page (approx. 15 items) of the EORTC QLQ-C30 between each mode as a distractor. Item scores by mode were compared using intraclass correlation coefficients (ICC); differences in scores within the 3-mode crossover design were evaluated with mixed-effects models. Difficulties with each mode experienced by participants were also assessed.Results: 103 (92 %) completed questionnaires by all three modes. The median ICC comparing tablet vs IVRS was 0.78 (range 0.55-0.90); tablet vs paper: 0.81 (0.62-0.96); IVRS vs paper: 0.78 (0.60-0.91); 89 % of ICCs were ≥0.70. Item-level mean differences by mode were small (medians [ranges] for tablet vs. IVRS = -0.04 [-0.16-0.22]; tablet vs paper = -0.02 [-0.11-0.14]; IVRS vs paper = 0.02 [-0.07-0.19]), and 57/81 (70 %) items had bootstrapped 95 % CI around the effect sizes within +/-0.20. The median time to complete the questionnaire by tablet was 3.4 min; IVRS: 5.8; paper: 4.0. The proportion of participants by mode who reported "no problems" responding to the questionnaire was 86 % tablet, 72 % IVRS, and 98 % paper.Conclusions: Mode equivalence of items was moderate to high, and comparable to test-retest reliability (median ICC = 0.80). Each mode was acceptable to a majority of respondents. Although the study was powered to detect moderate or larger discrepancies between modes, the observed ICCs and very small mean differences between modes provide evidence to support study designs that are responsive to patient or investigator preference for mode of administration, and justify comparison of results and pooled analyses across studies that employ different PRO-CTCAE modes of administration.Trial Registration: NCT Clinicaltrials.gov identifier: NCT02158637. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
27. Dana-Farber Moves to Retract, Correct Dozens of Cancer Papers Amid Allegations.
- Author
-
Worcester, Sharon
- Subjects
DISMISSAL of employees ,SPECIALTY hospitals ,FRAUD in science ,ARTIFICIAL intelligence ,CANCER treatment ,MULTIPLE myeloma ,MEDICAL research - Abstract
The article focuses on Dana-Farber Cancer Institute's actions to retract at least six research papers and correct 31 others following allegations of data manipulation, including papers authored by high-ranking officials on topics such as multiple myeloma and immune cells. Topics include the investigation sparked by a blog post highlighting image manipulation and errors in nearly 60 papers published between 1997 and 2017, and the specific irregularities noted by the blogger.
- Published
- 2024
28. Cancer nanomedicines: So many papers and so few drugs!
- Author
-
Venditto, Vincent J. and Szoka, Francis C.
- Subjects
- *
NANOMEDICINE , *CANCER treatment , *ANTINEOPLASTIC agents , *BUSINESS models , *DRUG approval , *MONOCLONAL antibodies , *MEDICAL polymers , *LIPOSOMES , *CLINICAL trials - Abstract
Abstract: This review identifies a timeline to nanomedicine anticancer drug approval using the business model of inventors, innovators and imitators. By evaluating the publication record of nanomedicine cancer therapeutics we identified a trend of very few publications prior to FDA approval. We first enumerated the publications related to cancer involving polymers, liposomes or monoclonal antibodies and determined the number of citations per publication as well as the number of published clinical trials among the publications. Combining these data with the development of specific nanomedicines, we are able to identify an invention phase consisting of seminal papers in basic science necessary for the development of a specific nanomedicine. The innovation phase includes the first report, the development and the clinical trials involving that nanomedicine. Finally, the imitation phase begins after approval when others ride the wave of success by using the same formulation for new drugs or using the same drug to validate other nanomedicines. We then focused our analysis on nanomedicines containing camptothecin derivatives, which are not yet approved including two polymers considered innovations and one liposomal formulation in the imitation phase. The conclusion that may be drawn from the analysis of the camptothecins is that approved drugs reformulated in polymeric and liposomal cancer nanomedicines have a more difficult time navigating through the approval process than the parent molecule. This is probably due to the fact that for most currently approved drugs, reformulating them in a nanocarrier provides a small increase in performance that large pharmaceutical companies do not consider being worth the time, effort and expense of development. It also appears that drug carriers have a more difficult path through the clinic than monoclonal antibodies. The added complexity of nanocarriers also deters their use to deliver new molecular entities. Thus, the new drug candidates that might be most improved by drug delivery in nanocarriers are not formulated in this fashion. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
29. The Role of High Frequency Dynamic Threshold (HiDT) Serum Carcinoembryonic Antigen (CEA) Measurements in Colorectal Cancer Surveillance: A (Revisited) Hypothesis Paper.
- Author
-
Grossmann, Irene, Verberne, Charlotte, de Bock, Geertruida, Havenga, Klaas, Kema, Ido, Klaase, Joost, Renehan, Andrew, and Wiggers, Theo
- Subjects
- *
COLON cancer , *EARLY detection of cancer , *CARCINOEMBRYONIC antigen , *CANCER treatment , *COLON diseases , *CANCER patients , *BLOOD plasma - Abstract
Following curative treatment for colorectal cancer (CRC), 30% to 50% of patients will develop recurrent disease. For CRC there are several lines of evidence supporting the hypothesis that early detection of metachronous disease offers a second opportunity for cure. This paper revisits the potential role of serum carcinoembryonic antigen (CEA) in follow-up. A comprehensive review of the literature (1978-2008) demonstrates that the initial promise of serum CEA as an effective surveillance tool has been tarnished through perpetuation of poorly designed studies. Specific limitations included: testing CEA as only an 'add-on' diagnostic tool; lack of standardization of threshold values; use of static thresholds; too low measurement frequency. Major changes in localizing imaging techniques and treatment of metastatic CRC further cause a decrease of clinical applicability of past trial outcomes. In 1982, Staab hypothesized that the optimal benefit of serum CEA as a surveillance tool is through high-frequency triage using a dynamic threshold (HiDT). Evidence supporting this hypothesis was found in the biochemical characteristics of serum CEA and retrospective studies showing the superior predictive value of a dynamic threshold. A multi-centred randomized phase III study optimizing the usage of HiDT against resectability of recurrent disease is commencing recruitment in the Netherlands. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
30. The medical treatment of metastatic renal cell cancer in the elderly: Position paper of a SIOG Taskforce
- Author
-
Bellmunt, Joaquim, Négrier, Sylvie, Escudier, Bernard, Awada, Ahmad, and Aapro, Matti
- Subjects
- *
CANCER treatment , *RENAL cancer , *NEPHROBLASTOMA , *RENAL cell carcinoma , *DRUG therapy - Abstract
Abstract: Treatments currently recommended for metastatic renal cell cancer (mRCC) have not been evaluated specifically in elderly patients. Here we consider what may be learned by analysing according to age the efficacy and toxicity data from key phase III trials of the targeted agents sorafenib (Nexavar), sunitinib (Sutent), temsirolimus (Torisel), and bevacizumab (Avastin), and from a study of expanded access to sunitinib and sorafenib. This paper represents the first systematic review of the role of targeted agents specifically in the elderly population. Retrospective subgroup analyses of clinical trial data cannot be considered definitive. However, they suggest in general that the progression-free and overall survival benefits seen in mRCC patients aged 65 years and over are similar to those in the younger age group. The frequency of major toxicities in elderly patients treated with targeted agents is no greater than in younger patients, although such toxicities may have greater impact on the quality of life. That said, no meaningful data are available for patients over 85 years. To confirm and extend these conclusions, prospective studies should be undertaken in the elderly to determine whether recommendations made for the wider mRCC population apply equally to this group of patients in whom comorbidities, comedication and the greater impact of low-grade toxicity may influence the efficacy and tolerability of treatment. Such studies are increasingly needed, given the growing number of elderly people and their rising life expectancy. Meanwhile, when considering the most appropriate drug to use in a particular patient, the toxicity profiles of the individual targeted agents – and any implications for specific comorbid conditions – should be taken into account. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
31. Bringing Access to the Full Spectrum of Cancer Research: A Call for Papers.
- Author
-
null, null
- Subjects
- *
CANCER research , *CANCER treatment - Abstract
The PLOS Medicine editors issue a call for papers for translational and clinical cancer research papers with strong potential to advance patient care, public policy, or clinical research agendas. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
32. Current research and treatment for epithelial ovarian cancer A Position Paper from the Helene Harris Memorial Trust
- Author
-
Balkwill, F., Bast Jr., R.C., Berek, J., Chenevix-Trench, G., Gore, M., Hamilton, T., Jacobs, I., Mills, G., Souhami, R., Urban, N., Ursulic, S., and Smyth, J.
- Subjects
- *
OVARIAN cancer , *CANCER treatment , *MOLECULAR genetics - Abstract
In March 2003, an international mulltidisciplinary group of scientists and clinicians with a specific interest in ovarian cancer met for 4 days to discuss research into and treatment of this challenging disease. Under the headings of molecular genetics, molecular biology, the biology of ovarian cancer, old therapies, new targets and the early detection of the disease, this Position Paper summarises the presentations and discussion from the 9th Biennial Helene Harris Memorial Trust Forum on Ovarian Cancer. In particular, we highlight the potential of international collaborations in translating laboratory science into useful clinical interventions. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
33. Invited Papers (4-12).
- Subjects
- *
CANCER treatment , *DRUG therapy , *CANCER cells , *TRANSPLANTATION of organs, tissues, etc. , *DNA , *NUCLEIC acids - Abstract
The article reports on several research papers related to cancer and its treatment. It informs that loss of the apoptotic response has been implicated in carcinogenesis as a consequence of increased survival of DNA-damage bearing cells. Many cancer cells have an inherent resistance to chemotherapy due to the abnormal expression of anti-apoptosis genes. The increased risk of cancer in immunosuppressed patients after organ transplantation, and in patients with inherited defects in immune function, such as severe combined immune deficiency, was thought to support the immune surveillance hypothesis.
- Published
- 2002
- Full Text
- View/download PDF
34. Cancer research in the United States: Dying by a thousand paper cuts.
- Author
-
Kantarjian, Hagop, Stewart, David J., and Zwelling, Leonard
- Subjects
- *
CANCER research , *HEALTH of cancer patients , *GUIDELINES , *CANCER diagnosis , *CANCER treatment - Abstract
The authors discuss cancer research in the United States and the implications of bureaucratic burdens on the conduct and cost of research and, consequently, the cost of drugs and health care. They propose potential remedial solutions. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
35. Clinical and Basic Research Papers - October 2011.
- Author
-
Ferrari, Serge, Seeman, Ego, Clézardin, Philippe, Karasik, David, Little, David G., and Matsumoto, Toshio
- Subjects
- *
DIPHOSPHONATES , *CANCER treatment , *BONE diseases , *ELECTROMAGNETIC fields , *BONE fractures , *OSTEOCYTES , *SOMATOTROPIN - Abstract
The article presents various uses of bisphosphonates in treatment of cancer and bone disorders. The article further presents details about clinical studies using pulsed electromagnetic field for tibial fractures, bone modeling, use of osteocytes in bone remodeling and repair and also about the drug effects. The physiology and metabolism of growth hormone, follicle-stimulating hormone and thyroid-stimulating hormone is also presented.
- Published
- 2011
- Full Text
- View/download PDF
36. RESEARCH PAPER: Nearby inverted repeats fuse to generate acentric and dicentric palindromic chromosomes by a replication template exchange mechanism.
- Author
-
Mizuno, Ken'Ichi, Lambert, Sarah, Baldacci, Giuseppe, Murray, Johanne M., and Carr, Antony M.
- Subjects
- *
CANCER invasiveness , *CANCER treatment , *DRUG resistance , *POLYMERASE chain reaction , *KARYOKINESIS , *CHROMOSOMES - Abstract
Gene amplification plays important roles in the progression of cancer and contributes to acquired drug resistance during treatment. Amplification can initiate via dicentric palindromic chromosome production and subsequent breakage?"fusion?"bridge cycles. Here we show that, in fission yeast, acentric and dicentric palindromic chromosomes form by homologous recombination protein-dependent fusion of nearby inverted repeats, and that these fusions occur frequently when replication forks arrest within the inverted repeats. Genetic and molecular analyses suggest that these acentric and dicentric palindromic chromosomes arise not by previously described mechanisms, but by a replication template exchange mechanism that does not involve a DNA double-strand break. We thus propose an alternative mechanism for the generation of palindromic chromosomes dependent on replication fork arrest at closely spaced inverted repeats. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
37. Superficial skin cancer therapy with Y‐90 microspheres: A feasibility study on patch preparation.
- Author
-
Pashazadeh, Ali, Landes, Rainer, Boese, Axel, Kreissl, Michael C., Klopfleisch, Maurice, and Friebe, Michael
- Subjects
SKIN cancer ,BETA rays ,CANCER treatment ,MICROSPHERES ,NITROCELLULOSE ,SKIN permeability ,RADIOISOTOPE brachytherapy ,NANOFABRICATION - Abstract
Background: Radiation therapy using beta particles is an interesting treatment for very superficial skin lesions. Due to their low penetration in tissue and rapid dose fall‐off, beta particles can protect underlying bony structures and surrounding healthy tissue while irradiating the skin tumor. In the current work, a simple method for the fabrication of a radioactive patch for use in skin cancer therapy based on a beta‐emitting isotope is presented. Materials and methods: The beta radiation sources were Y‐90 microspheres currently used for catheter‐based radioembolization of unresectable liver tumors. The microspheres were filtered through a syringe filter to trap them on the cellulose nitrate paper of the filter and create a radioactive patch. In the current study, to avoid the need for a hot laboratory, the experiment was done using nonradioactive microspheres. An optical microscope was used to verify the distribution of the particles on the filter paper. Results: Visual evaluation of the patches showed that using the proposed method, therapeutic skin patches with a fairly uniform distribution of microspheres can be created. Conclusion: The proposed simple method may be used in creating radiotherapeutic patches using Y‐90 microspheres for radiation therapy of thin skin lesions located close to sensitive structures. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
38. Synthesis and photo-conversion of androsta- and pregna-5,7-dienes to vitamin D3-like derivativesThis paper was published as part of the themed issue in honour of Nicholas Turro.Electronic supplementary information (ESI) available: HPLC chromatogram, UV spectra and additional experimental data for irradiation products of androsta- and pregna-5,7-dienes. NMR spectra for 5a, 5aD, 5aLand 5aTand Table of shifts for androsta- and pregna-5,7-dienes. See DOI: 10.1039/b809005j
- Author
-
Michal A. Zmijewski, Wei Li, Jordan K. Zjawiony, Trevor W. Sweatman, Jianjun Chen, Duane D. Miller, and Andrzej T. Slominski
- Subjects
- *
CANCER treatment , *CANCER hospitals , *ALTERNATIVE treatment for cancer , *DIET therapy for cancer patients - Abstract
Calcitriol (3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-1α,3β,25-triol) is a powerful oncostatic form of vitamin D3 that is of limited clinical utility due to hypercalcemic (toxic) effects. Since the removal of the side chain reduces or eliminates the calcemic activity of vitamin D3, secosteroidal compounds lacking or with a shortened side chain are good candidates for anti-cancer drugs. In addition, 5,7-steroidal dienes without a side chain can be generated in vivounder pathological conditions. A series of androsta- and pregna-5,7-dienes was efficiently synthesized from their respective 3-acetylated 5-en precursors by bromination-dehydrobromination and deacetylation reactions. Ultraviolet B (UVB) irradiation was used to generate corresponding 9,10-secosteroids with vitamin D-like structures. Additional products with tachysterol-like (T-like) structures or 5,7-dienes with inverted configuration at C-9 and C-10 (lumisterol, L-like) were also detected. Different doses of UVB resulted in formation of various products. At low doses, previtamin D-, T- or L-like compounds were formed as the main products, while higher doses induced further isomerization, with formation of potentially oxidized derivatives. In summary, we describe dynamic UVB induced conversion of androsta- and pregna-5,7-dienes into vitamin D-like compounds and their rearranged analogues; additionally novel T-like and L-like structures were also produced and characterized. Further biological evaluation of newly synthesized compounds should help to select the best candidate(s) for potential treatment of hyperproliferative diseases including cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
39. Abstracts of Scientific Papers Presented at the 11th Annual Meeting of the Biofeedback Foundation of Europe.
- Subjects
- *
PSYCHOLOGY , *SOCIAL interaction , *ELECTROENCEPHALOGRAPHY , *PHYSIOLOGICAL control systems - Abstract
The article presents abstracts on psychological topics which include biofeedback, social interaction and electroencephalography.
- Published
- 2007
- Full Text
- View/download PDF
40. Management of cancer treatment-induced bone loss in early breast and prostate cancer - a consensus paper of the Belgian Bone Club.
- Author
-
Body, J. J., Bergmann, P., Boonen, S., Boutsen, Y., Devogelaer, J. P., Goemaere, S., Reginster, J. Y., Rozenberg, S., and Kaufman, J. M.
- Subjects
- *
CANCER treatment , *BREAST cancer , *PROSTATE cancer risk factors , *DIPHOSPHONATES , *DISEASE management , *CANCER chemotherapy , *OLDER people - Abstract
Cancer treatment-induced bone loss (CTIBL) is one of the most important side effects of adjuvant antineoplastic treatment in hormone-dependent neoplasms. Chemotherapy, GnRH analogs and tamoxifen can induce marked bone loss in premenopausal women with early breast cancer. Aromatase inhibitors (AIs) are replacing tamoxifen as the preferred treatment for postmenopausal women. As a class effect, steroidal (exemestane) and non-steroidal (anastrozole and letrozole) AIs increase bone turnover and cause bone loss (4%–5% over 2 years). When compared to tamoxifen, the risk of getting a clinical fracture under AI treatment is increased by 35%–50%. In patients with prostate cancer, androgen deprivation therapy (ADT) increases bone turnover, reduces bone mass (4%–5% per year) and increases the fracture rate depending on the duration of therapy. Zoledronic acid can prevent accelerated bone loss induced by goserelin in premenopausal women, by letrozole in postmenopausal women and by ADT in men. More limited data indicate that weekly alendronate or risedronate could also be effective for preventing CTIBL. Initiation of therapy early, prior to the occurrence of severe osteoporosis, rather than after, may be more effective. Bisphosphonate treatment should be considered in osteoporotic but also in osteopenic patients if other risk factor(s) for fractures are present. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
41. Hot Papers in the Literature.
- Subjects
- *
MEDICAL research , *DRUG therapy , *DISEASES in women , *MENOPAUSE , *CANCER treatment - Abstract
The article presents abstract of medical research. They include "Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status", "Hypertension, menopause, and coronary artery disease risk in the Women's Ischemia Syndrome Evaluation (WISE) Study" and "Neoadjuvant chemotherapy in vulvar cancer: Avoiding primary exenteration".
- Published
- 2006
- Full Text
- View/download PDF
42. Invited Papers 2.
- Subjects
- *
CANCER research , *COLON cancer , *ALKYLATING agents , *DRUG therapy , *ADENOVIRUSES , *CANCER treatment - Abstract
The article presents several studies related to cancer research. Certain alkylating agents because of their toxic properties, are also used for cancer chemotherapy. These affect very different target cell populations. Results on its study demonstrate that global cellular responses to alkylation damage are far more complex than first thought. It also discusses about replicating adenoviruses that target colon cancer. Adenoviruses that were developed, selectively replicate in cells with activated Wnt signaling by inserting binding sites for the Tcf family of transcription factors in the early promoters of human adenovirus 5.
- Published
- 2004
- Full Text
- View/download PDF
43. research paper Early response to therapy and survival in multiple myeloma.
- Author
-
Schaar, C. G., Kluin-Nelemans, J. C., le Cessie, S., Franck, P. F. H., te Marvelde, M. C., and Wijermans, P. W.
- Subjects
- *
MULTIPLE myeloma , *CANCER treatment , *DRUG therapy , *MONOCLONAL antibodies , *IMMUNOGLOBULIN M , *PREDNISONE - Abstract
Whether the response to chemotherapy is a prognosticator in multiple myeloma (MM) is still not known. Therefore, the relationship between survival and the rate of monoclonal protein (M-protein) decrement during the first cycles of therapy was prospectively assessed in 262 patients with newly diagnosed MM that were included in a phase III trial (HOVON-16). M-proteins were collected monthly during melphalan–prednisone therapy (MP: melphalan 0·25 mg/kg, prednisone 1·0 mg/kg orally for 5 d every 4 weeks). Patients with light chain disease ( n = 18), immunoglobulin M (IgM)-MM ( n = 1) and no immunotyping ( n = 1) were excluded. Of the 242 patients studied, 75% had IgG M-protein and 25% IgA; MM stages: I: 1%, II: 35% and III: 64%. The median M-protein decrease after the first cycle of MP was 21% for IgG and 27% for IgA, and declined to < 5% after four cycles. An obvious survival advantage was seen for patients who had an M-protein decrease of at least 30% after the first MP cycle, which became significant when an M-protein decrease of 40% or more was reached. As established prognostic parameters (Salmon & Durie stage, serum creatinine, and haemoglobin) also remained prognostically significant, we concluded that early response to MP predicts for survival in MM. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
44. Title of presented paper: Melatonin in cancer treatment.
- Author
-
Dyndał, Kinga, Czerkiewicz, Karolina, and Cybula, Paweł
- Subjects
MELATONIN ,CANCER treatment ,NEUROHORMONES ,HORMONE therapy ,RADIOTHERAPY - Abstract
Introduction and aim. Melatonin, a neurohormone involved in the regulation of the sleep-wake cycle, is produced in the human body, mainly in the pineal gland. An increasing number of evidence, suggests that this amine may be an essential new target (adjuvant) in cancer treatment. The oncostatic and anticancer properties of melatonin have been demonstrated in various types of cancer. The tumor suppressive function of melatonin is exerted through different interactions with cell surface receptors such as MT1 and MT2 melatonin receptors. Material and methods. A literature review was performed by analyzing randomized controlled trials (RCTs) and systematic reviews from PubMed/MEDLINE and Embase published in the last five years. For the literature search, we used the following keywords: *melatonin in cancer, *novel cancer therapy, and *hormonal therapy. Analysis of literature. Studies have shown that melatonin may induce anti-tumor effects through multiple mechanisms, including inhibition of tumor growth and angiogenesis, induction of apoptosis, inhibition of cell proliferation, modulation of the immune response, and augmentation of the therapeutic effects of conventional anticancer therapies. In addition, melatonin decreased some of the side effects caused by radiotherapy and chemotherapy, such as asthenia, thrombocytopenia, leukopenia, and nausea. Conclusion. Melatonin may improve sleep and quality of life in cancer patients, relieve anxiety in most patients, and reduce the risk of developing depressive symptoms. Melatonin has also shown great potential as a safe and effective complementary therapy for cancer treatment with minimal side effects and low toxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2023
45. Invited Papers (1-3).
- Subjects
- *
CANCER treatment , *DRUG therapy , *RADIOTHERAPY , *PANCREAS , *THERAPEUTICS , *CANCER - Abstract
The article reports on several research papers related to cancer and its treatment. It states that intensive, high dose therapy with meiphalan yields high remission rates but evidence on survival benefits has been inconclusive. It also focuses on the roles of adjuvant chemoradiotherapy and adjuvant chemotherapy in pancreatic cancer remain uncertain. The article also reveals that removing the internal mammary nodes remains a difficult routine procedure. Due to the relatively small percentage of patients that have positive internal mammary nodes with negative axillary status. The roles of adjuvant chemoradiotherapy and adjuvant chemotherapy in pancreatic cancer remain uncertain.
- Published
- 2002
- Full Text
- View/download PDF
46. Investigating the potential application of organic and non-organic nanoparticles for gastric cancer treatment: An evidence-based review.
- Author
-
Moradifar, N., Moayyedkazemi, A., Mohammadi, H. R., Ahmadi, S., and Raziani, Y.
- Subjects
STOMACH cancer ,NANOPARTICLES ,METAL nanoparticles ,CANCER treatment ,CANCER-related mortality - Abstract
Gastric cancer, which is considered a major health concern, is the sixth most frequent cancer and the second leading cause of cancer-related mortality across the globe. The present survey aimed to systematically review the anti-gastric cancer effect of all organic and inorganic nanoparticles (NPs) in in vitro, in vivo, and clinical trials. The investigation followed the PRISMA guidelines, and the findings were recorded in the CAMARADES-NC3Rs Preclinical Systematic Review and Meta-Analysis Facility database. A detailed search was conducted on various English databases, such as Scopus, Web of Science, EMBASE, PubMed, and Google Scholar, with no specified publication time frame to obtain papers regarding the anti-gastric cancer properties of nanoparticles. The search process was performed using the following terms: "Nanoparticles," "Gastric cancer," "Antigastric cancer," "Metal nanoparticles," "Organic nanoparticles," "Inorganic nanoparticles, "in vitro," "Clinical," and "in vivo,". Out of 11,189 papers, 31 articles, including 19 (45.5%) in vitro, 3 (13.6%) in vivo, 3 (13.6%) clinical trials, and 6 (27.3%) in vitro/in vivo, up to 2023, met the inclusion criteria for discussion in this systematic review. The most widely used NPs were found to be organic nanoparticles, such as polylactic acid and poly lactic-co-glycolic acid (16, 80.0%), followed by inorganic nanoparticles, such as silver NPs (13, 41.9.0%). This review study highlighted the high anti-gastric cancer potential of a wide range of organic and non-organic NPs through their activity via some mechanisms, such as the induction of apoptosis, gene therapy, and drug delivery. Nonetheless, further studies, especially in clinical settings, are needed to confirm their anti-gastric effects and accurate mechanisms. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. Position paper by the UKCCCR Elderly Cancer Patients in Clinical Trials Working Group.
- Subjects
- *
OLDER people , *CANCER treatment , *CLINICAL trials - Abstract
Summarizes the proceedings of the UKCCCR Trials Committee related to management of elderly cancer patients and their entry into clinical trials. Terms of reference set by the working group of UKCCCR; Problems related to clinical trials of elderly cancer patients; Representation of elderly patients in trials; Reasons for poor entry of elderly in clinical trials; Problems related to toxicity of treatment.
- Published
- 2000
- Full Text
- View/download PDF
48. Predictors of emotional distress a year or more after diagnosis of cancer: A systematic review of the literature.
- Author
-
Cook, Sharon A., Salmon, Peter, Hayes, Gemma, Byrne, Angela, and Fisher, Peter L.
- Subjects
PSYCHOLOGICAL distress ,MENTAL health ,CANCER diagnosis ,CANCER treatment ,NEUROTICISM ,ONCOLOGY - Abstract
Objective: Why some people recover emotionally after diagnosis and treatment of cancer and others do not is poorly understood. To identify factors around the time of diagnosis that predict longer-term distress is a necessary step in developing interventions to reduce patients' vulnerability. This review identified the demographic, clinical, social, and psychological factors available at or within 3 months of diagnosis that are reliable predictors of emotional distress at least 12 months later.Methods: A systematic search of literature for prospective studies addressing our research question and predicting a range of distress outcomes was conducted. Thirty-nine papers (reporting 36 studies) were subjected to narrative synthesis of the evidence.Results: There was no consistent evidence that demographic, clinical, or social factors reliably predicted longer-term distress. Of the psychological factors examined, only baseline distress (significant in 26 of 30 relevant papers; 24 of 28 studies) and neuroticism (significant in all 5 papers/studies that examined it) consistently predicted longer-term distress. The heterogeneity of included studies, particularly in populations studied and methodology, precluded meta-analytic techniques.Conclusions: This review supports current clinical guidance advising early assessment of distress as a marker of vulnerability to persistent problems. Additionally, neuroticism is also indicated as a useful marker of vulnerability. However, the review also highlights that more sophisticated research designs, capable of identifying the psychological processes that underlie the association between these marker variables and persistent distress, are needed before more effective early interventions can be developed. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
49. Threshold-awareness in adaptive cancer therapy.
- Author
-
Wang, MingYi, Scott, Jacob G., and Vladimirsky, Alexander
- Subjects
CANCER treatment ,STOCHASTIC control theory ,DYNAMIC programming ,BUDGET ,QUALITY of life - Abstract
Although adaptive cancer therapy shows promise in integrating evolutionary dynamics into treatment scheduling, the stochastic nature of cancer evolution has seldom been taken into account. Various sources of random perturbations can impact the evolution of heterogeneous tumors, making performance metrics of any treatment policy random as well. In this paper, we propose an efficient method for selecting optimal adaptive treatment policies under randomly evolving tumor dynamics. The goal is to improve the cumulative "cost" of treatment, a combination of the total amount of drugs used and the total treatment time. As this cost also becomes random in any stochastic setting, we maximize the probability of reaching the treatment goals (tumor stabilization or eradication) without exceeding a pre-specified cost threshold (or a "budget"). We use a novel Stochastic Optimal Control formulation and Dynamic Programming to find such "threshold-aware" optimal treatment policies. Our approach enables an efficient algorithm to compute these policies for a range of threshold values simultaneously. Compared to treatment plans shown to be optimal in a deterministic setting, the new "threshold-aware" policies significantly improve the chances of the therapy succeeding under the budget, which is correlated with a lower general drug usage. We illustrate this method using two specific examples, but our approach is far more general and provides a new tool for optimizing adaptive therapies based on a broad range of stochastic cancer models. Author summary: Tumor heterogeneities provide an opportunity to improve therapies by leveraging complex (often competitive) interactions of different types of cancer cells. These interactions are usually stochastic due to both individual cell differences and random events affecting the patient as a whole. The new generation of cancer models strive to account for this inherent stochasticity, and adaptive treatment plans need to reflect it as well. In optimizing such treatment, the most common approach is to maximize the probability of eventually stabilizing or eradicating the tumor. In this paper, we consider a more nuanced version of success, maximizing the probability of reaching these therapy goals before the cumulative burden from the disease and treatment exceed a chosen threshold. Importantly, our method allows computing such optimal treatment plans efficiently and for a range of thresholds at once. If used on a high-fidelity personalized model, our general approach could potentially be used by clinicians to choose the most suitable threshold after a detailed discussion of a specific patient's goals (e.g., to include the trade-offs between toxicity and quality of life). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Advances in CAR-NK cell therapy for lung cancer: is it a better choice in the future?
- Author
-
Fengqin Liu, Xia Miao, Lu Han, and Xiao Song
- Subjects
LUNG cancer ,CELLULAR therapy ,CYTOKINE release syndrome ,CANCER treatment ,CHIMERIC antigen receptors - Abstract
Lung cancer remains one of the leading causes of cancer-related mortality worldwide necessitating the development of innovative therapeutic strategies. Chimeric antigen receptor (CAR) natural killer (NK) cell therapy represents a promising advancement in the field of oncology offering a novel approach to target and eliminate tumor cells with high specificity and reduced risk of immune-related adverse effects. This paper reviews the mechanism, potential targets, and recent advances in CAR-NK cell therapy for lung cancer, including the design and engineering of CAR-NK cells, preclinical studies, and the outcomes of early-phase clinical trials. We highlight the unique advantages of using NK cells, such as their innate ability to recognize and kill cancer cells and their reduced potential for inducing graft-versus-host disease (GvHD) and cytokine release syndrome (CRS) compared to CAR T-cell therapies. Results from recent studies demonstrate significant antitumor activity in lung cancer models with improved targeting and persistence of CAR-NK cells observed in vitro and in vivo. Finally, we discuss the challenges in optimizing CAR-NK cell therapies, including the potential resistance mechanisms. The paper concludes with an outlook on the future directions of CAR-NK cell research and its implications for lung cancer treatment emphasizing the importance of continued innovation and collaboration in the field. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.